Antitope Announces EpiScreen Agreement With GlaxoSmithKline

5th May 2009 -Antitope Ltd., a Cambridge (UK)-based biotechnology company specialising in immunogenicity testing and engineering of therapeutic antibodies/proteins, today announced the signing of a further research collaboration with GlaxoSmithKline plc. (GSK). Under the collaboration, Antitope will apply its proprietary EpiScreen technology for preclinical assessment of immunogenicity to a selected group of GSK's biopharmaceutical.